Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) has announced the development of EMBARKCT, a scalable version of its groundbreaking EMBARK Training Program. The initiative aims to enhance the company’s ability to screen, qualify, train and certify facilitators for future pivotal studies.
The program is designed to provide foundational training to facilitators, enabling them to offer skillful and ethical care in the field of psychedelic therapeutics.
The EMBARKCT program is a significant evolution of the original EMBARK program, launched in October 2021. It is specifically designed to enhance Cybin’s ability to improve the training for future pivotal studies of its lead drug candidates, CYB003 and CYB004.
The substances are deuterated psilocybin and dimethyltryptamine (DMT) analogs, respectively, being developed for the potential treatment of major depressive disorder and generalized anxiety disorder.
“The evolution of the EMBARK Training Program to EMBARKCT enhances our capacity to deliver high-quality, scalable facilitator training suitable for a multisite, global clinical trial,” Cybin’s Head of Therapies Alex Kelman said.
Read more: Windsor police raid new mushroom dispensary, owners open up shop next day
Read more: NeoLumina Bioscience to develop Filament Health patented psilocybin as eating disorders treatment
In addition to the EMBARKCT program, Cybin has also launched EMBARK Open Access (EMBARK OA), a free online training course for psychedelic facilitation.
This platform has laid the groundwork for expanding access to training resources and may serve as a bridge for facilitators to enroll in future EMBARK training programs and potentially participate in future Cybin-sponsored clinical trials.
As Cybin continues to enhance its EMBARK facilitator training programs, the company has recognized the American Medical Association’s newly published language for new Current Procedural Terminology (CPT) III codes.
These codes, which take effect from Jan. 1, 2024, are intended to support potential reimbursement of in-person monitoring and support provided during psychedelic therapy administration.
The company established a standardized way to identify a procedure and is intended to allow data to be collected to support broader use or a potential U.S. Food and Drug Administration (FDA) approval process.
Read more: Calgary’s ATMA launches psychedelic-assisted therapy training course for physicians
Read more: Numinus partners with HealingMaps to promote its clinics and identify expansion targets
Several institutions and organizations in Canada offer training in psychedelic therapy
In Canada, a number of institutions and organizations are pioneering the field of psychedelic therapy training.
One such institution is Vancouver Island University, which offers a specialized Psychedelic-assisted Therapy Graduate Certificate program. This program is specifically designed for professional therapists and clinicians who are looking to broaden their expertise.
In addition to academic institutions, there are also organizations like ATMA Journey Centers that are making strides in this field. ATMA provides comprehensive psychedelic therapy education and training to practitioners, equipping them with the necessary skills to offer this groundbreaking treatment.
Meanwhile, the non-profit TheraPsil offers a unique approach to training, which includes in-person training seminars and clinical supervision. This hands-on approach ensures that trainees gain practical experience in psychedelic therapy.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) is also contributing to the field with its innovative Practitioner Certification Pathway. This eight-week virtual course program allows practitioners to learn Numinus’ model of care for psychedelic-assisted therapy, providing a flexible learning option for busy professionals.
